News

For the first quarter of 2009, GAAP income from operations was $5.2 million, compared to $4.4 million in the first quarter of 2008. The company reported total revenues

The net income for the first quarter of 2009 is due to the recognition of non-cash deferred revenue and a decrease in total operating expenses, said Dynavax. The

For the first quarter of 2009, Bristol-Myers Squibb reported diluted earnings per share of $0.32, a decrease of 3%, compared to $0.33 for the same period of 2008.

VaxInnate, a biotechnology company, has reported positive results from the Phase I study of VAX125, the company’s investigational hemagglutinin-flagellin flu vaccine. The flu vaccine was found to be

For the first quarter of 2009, Sanofi has reported adjusted earnings per share of E1.67, an increase of 16.8%, compared to adjusted earnings per share of E1.43 for

Sweden-based specialty pharmaceutical company Pharmalink has completed its open Phase II trial evaluating the efficacy and safety of Nefecon in IgA nephropathy, a glomerulonephritis leading to end-stage renal

Oxford BioMedica will receive an upfront payment of $26 million and committed funding of up to a further $24 million over three years. In addition, Sanofi-Aventis has an

Belgium-based biopharmaceutical and specialty chemical company UCB has reported top-line results from two Phase III clinical studies to assess the efficacy and safety of brivaracetam as adjunctive treatment

Shoppers Drug Mart has reported that its net earnings for the first quarter ended March 28, 2009 increased 6.1% to C$107m or C$0.49 per diluted share, compared to